Answers from our expert faculty to attendee questions submitted during the 2026 live board review sessions.

R. Sean Morrison

R. Sean Morrison, MD, FAAHPM

Still to be developed to my knowledge – assuming this is home based palliative care.

Enforceable quality standards, condition of participation in Medicare for hospitals, Medicare ambulatory care benefit.

Probably not as on-line training does not replace clinical experience. a combination might be the way to go – mid-career fellowships like we have in palliative care.

Agree.

Michael Kaplan

Michael Kaplan, MD

I have no good answer for this. This is unfortunate for patients and I hope they reconsider their policy! May be helpful to meet up with them by phone or in person to discuss your concerns, particularly bc seronegative RA is most common RA in geriatric population. If their pain melts away with pred 5, that’s another piece of data you could use to get them in, perhaps? Also may be useful to partner virtually with a rheumatologist as able though exam is king in rheum. This is really tough and I’m sorry to hear about it.

OP tx benefits anyone with OP including early dz and late disease. When treated earlier you preserve more bone mass. Most important part of OP treatment is getting strong (resistance training) and stability, and this can be done at any time, again ideally as early as possible.

Age adjusted ESR applies to all disease. CRP is not age adjusted.

Cynthia Boyd

Cynthia Boyd, MD, MPH

Answer coming soon!

Answer coming soon!

Answer coming soon!

Answer coming soon!

Answer coming soon!

Answer coming soon!

Answer coming soon!

Mary Sano

Mary Sano, PhD

Answer coming soon!

Answer coming soon!

Answer coming soon!

Answer coming soon!

Ritchell Dignam

Ritchell Dignam, MD

Yes, hospice patients can see specialists. While hospice focuses on comfort, it does not necessarily mean eliminating all other medical care. It is helpful to explore the reason why the patient sees their specialist. If the reason for seeing the specialist is related to the terminal illness, the hospice generally coordinates and covers the specialist care if management is palliative in nature and fits the hospice plan of care. If the visit is due to an unrelated condition, the patient can usually continue to see the specialists and use the regular insurance or Medicare. In summary, it is always good to review and discuss with the patients, and their healthcare agent/surrogate the reason for following up with the specialist to avoid coverage or coordination problems.

Yes, I have seen both situations. Clinicians may not raise or recommend hospice for some reasons such as (but not limited to): the primary physician may not know that a specialist has recommended hospice or when family requested hospice evaluation, clinicians feel that prognosis can be difficult to predict, some clinicians may be uncomfortable discussing dying. There are studies that show hospice eligible patients never have the hospice conversation. On the patient and families declining hospice care also have reasons that I have encountered such as, some are “not ready”, some want more “treatment”, some do not understand what hospice care and its services/benefits are or some fear losing their current care team/doctors. Education both the medical community and community at large about hospice care, its benefits and care delivery by a team for hospice eligible patients is very helpful and is much needed. Always good to explore the reasons why hospice eligible patients are not referred or accept care to guide the future conversations with the hospice team, PCP and patients and families.

Hospice patients may continue to chronic disease management especially when it supports comfort and quality of life. As mentioned at the meeting, the treatment may shift from disease prevention or long-term control toward symptom relief and comfort. The hospice team will continue to coordinate care with the PCP (if there is one) or with the hospice physician to review medications, monitoring and treatments that should fit with the patients’ goals of care and hospice plan of care. It will be an on-going discussion of the goals of care and treatment to weigh the benefit vs burden or risk of continued treatment to optimize care. As a hospice physician, I discuss with the patient and families when treatment, lab monitoring or medication needs to be stopped if it is burdensome, or when offering little benefit. If the primary intention is to prolong life rather than comfort, this may not be aligned with the services offered under the benefit, and patient or health care agent have the right to revoke hospice for curative care . There should be collaboration and coordination of the care between the patient/family, PCP (Primary Care Physician) and hospice team to optimize end of life care, address goals and possibly discontinuation of the chronic disease management if no longer benefiting the patient, continued education of the patient and family of what hospice care is about.

Alexander Philip Gamble

Alexander Philip Gamble, MD

The literature suggests some patients may show benefit as early as two weeks but usually it can take 4 if not 6 weeks to see clear benefit (over placebo).

An important consideration in our patient populations and how we approach it will depend a lot on the specifics of a given patient scenario. In general terms we could start with an assessment of how urgent it is to start a given medication – in the acute setting QT prolongation may reflect metabolic imbalances or strain of illness that may improve as the patient does, so it may be more beneficial to wait to start treatment. Risk/benefit analysis may favor starting with non-pharmacologic approaches in treating mood issues like therapy or behavioral activation. When symptoms are more severe and seem clearly driven by depression (as opposed to underlying medical conditions) then risk should be discussed with the patient in a shared-decision-making model. All of that said, the risk of QT prolongation seems lower with some agents than others among the antidepressants, in most cases sertraline will be the first choice where QT prolongation is a concern.

Excellent question! Particularly in the acute setting a positive PHQ-2 or 9 should be followed by an appropriate clinical assessment – these screens can overestimate severity particularly on the basis of physical symptoms that might be more reflective of the acute illness. Ultimately medications will take weeks to have effect in any case so do not need to be in a rush to start treatment when it remains unclear whether low mood may be situation or driven by acute medical factors that might improve rapidly as their condition stabilizes and improves.

Careful history taking and observational data gathering will be essential in cases like these as it can be challenging to differentiate depression from cognitive disturbance particularly in more advanced dementia. In these cases consultation with geriatric psychiatry where available and/or neurology can be helpful in differentiating and targeting symptoms, although there will be times where shared-decision-making with surrogates may favor a trial of antidepressants with close monitoring to assess impact.

Olusegun Apoeso

Olusegun Apoeso, MBBS

Depends on Patients/family’s goals and regional health care support system

  • For a goal that is strictly comfort focused and no hospital/facility transfer, management will be dyspnea relief with opiates and anti-anxiety. There are multi-modal ways of administering morphine/oxycodone and lorazepam at home by caregivers where home hospice is available. In these instances, prognosis may be short and family should be prepared for a dying process at home.
  • Hospice may, never-the-less, advice facility transfer if assessment reveals that support needed, based of symptom burden, is not possible at home.

It’s mostly important to be curious and try to find out why. For example,

  • For some, it’s based on a cultural/religious belief system. Very unlikely that families will yield under these circumstances. Best to negotiate around rate of flow of the IVF and a joint agreement to discontinue if signs of fluid congestion/discomfort is noticed.

    Also important to share that the dying process may be prolonged by a few more days that might require using more medications to try and manage signs of discomfort secondary to the use of the excess fluid accumulation.

  • For others, it may be because of the desire to attain important milestones or visitation by loved ones. Best to offer same negotiating talking points as above.

    Families and loved ones mostly just want to know that we care and feel their distress around the process. Compassionate engagement often gets them to the place of understanding.

Sara K. Rostanski

Sara K. Rostanski, MD

Answer coming soon!

Answer coming soon!

Answer coming soon!

Veronica Rivera Sheila Barton

Veronica Rivera, MD & Sheila Barton, MSW

Veterans have different level of coverage that is determined by their “service connection”. This is basically related to if their medical issues are related to their military service. If a patient has low service connection, they probably want to get Medicare coverage as much as possible (A/B/D or managed C plan).

Given the landscape of our healthcare system, if someone will likely not be eligible for Medicaid in the future, it’s worth considering investing in LTC insurance, if that is financially viable. We’re not advising on this in our clinical care usually because it’s advised to enroll in LTC insurance earlier…usually between 50-60yrs of age. We are often seeing patients when they are older and it’s too late to enroll.

We did mention some of the cons of Part C — more restrictions on picking providers, more prior authorizations, etc. These are not usually the case for supplemental policies.

Carley Trentman

Carley Trentman, MD

Answer coming soon!

Answer coming soon!

Answer coming soon!

Winston Wey

Winston Wey, MD

I think it’s important to keep in mind which ones are validated and most popular. Generally, the most popular tools are the older tools that are referenced in many papers and likely utilized by the relevant specialties. It’s an exciting time now with many tools coming out, but very few of them have been validated and even fewer are popular/widespread. I will often talk to a specific specialty to see what tools they use, and if there are newer models that they seem to prefer.

Great question: with the FAST scale, typically it would be the level where there is no skipping. In your example, the patient would be FAST 6E instead of 7C because they are still able to speak intelligible sentences. Therefore this patient wouldn’t technically qualify for hospice, but in practice, hospice agencies sometimes make exceptions (as I mentioned in my talk, sometimes hospice agencies will accept 7A with 1+ medical condition instead of the Medicare criteria of 7C with 1+ medical condtion).

Paul Shekane

Paul Shekane, MD, FASA

I believe that thinking of interventional therapies in a stepwise approach (like a ladder of therapy) with interventions being on the final tier is flawed. Treating pain may require PT, acupuncture, CBT etc as well as interventions all at the same time. For example if we can help a patient’s symptom they may better participate in PT. We should be involved at any step in a chronic pain complaint.

Medial branch blocks lead to ablation nearly 90+% of the time especially with two positive diagnostic blocks. Phantom pain is not a common reason for us to do sympathetic blocks but can sometimes improve with it.

An older adult that cannot take medications due to side effects or comorbidities, someone that can hold anti coagulation if necessary and one that is not very needle phobic may benefit.

Isabella Newman

Isabella Newman, MD

Without obstruction, perforation, or peritonitis, I’d focus on relieving the stool burden with laxatives/enemas/disimpaction as indicated depending on the patient’s goals and what they can tolerate. Relieving the stool burden itself can be an important part of symptom management, while also weighing the discomfort and burden of repeated rectal or more invasive interventions against the expected symptomatic benefit.

I’d still use self-report whenever possible, but would rely more on observation, family and nursing input, and changes from the patient’s baseline. We have to remember that symptoms can present differently in this population- for example, constipation or fecal impaction can contribute to delirium rather than a patient reporting abdominal discomfort. We can also use validated observational tools when appropriate, like the PAINAD or CPOT for pain and RDOS for respiratory distress.

Nisha Rughwani

Nisha Rughwani, MD

Usually if the CAC score is 0, can think about repeating after 5 years, some data says 3-7 years depending on age and CVD risk.

If CAC>0 – useful to guide treatment. The screening guidelines are to try and understand if someone needs to start statins.

Most likely, yes, however it depends on the other chronic conditions the patient may have and how functionally and cognitively they are.

Currently there is no change in the guidelines and unclear what it will be in the future.

Ayla Pelleg

Ayla Pelleg, MD

Answer coming soon!

Answer coming soon!

Jacqueline Sheehan

Jacqueline Sheehan, MD

I’d first check what urine tox test is actually being ordered, because buprenorphine doesn’t usually show up on a standard opioid screen so a negative result may not necessarily mean the patient isn’t using their patch. Also, has the patient actually had the patch on when you’ve seen him at subsequent follow-up visits? That might be another helpful thing to confirm with patient. Even with a test specifically looking for buprenorphine, the patch delivers pretty low doses, so sometimes the levels in the urine are too low to detect.

Incomplete cross-tolerance is something we always need to consider when switching opioids. Fentanyl patches are a bit different, though, because the conversions are already designed to account for this, so we don’t need to apply a dose reduction for cross-tolerance.

Absolutely, buprenorphine isn’t just for patients with opioid use disorder. It’s also a good option for chronic pain in patients who need ongoing opioid therapy. It has some safety advantages, including a ceiling effect on respiratory depression, and can be continued long-term as long as it’s providing benefit and remains appropriate for the patient.

Oral short-acting opioids can be given as frequently as every 2 hours as needed, but practically speaking, especially in the outpatient setting, we typically prescribe them every 4 hours as needed. This also aligns with their usual duration of action. In terms of scheduling opioids, we generally consider this for patients with constant pain who have an ongoing need for opioid medication, rather than those with intermittent pain.

Shahla Baharlou Sharon See

Shahla Baharlou, MD & Sharon See, Pharm.D., FCCP, BCPS, BCGP

I don’t think we discussed any topic related to QTC? However, in my practice I follow upper limit of QTC of 470 men), and 480 (women) at which point I avoid prescribing antipsychotics (or any meds that can cause further prolongation of QTC).

Great questions. I would say it depends on the patient( health trajectory, stage of serious illness and their goals) and their medications, however medications like gabapentin which are with minimal benefit for pain( except for neuropathy) and or seizure might be one of the ones to consider tapering and or stopping. Another example is cholinesterase inhibitors in the setting of advanced dementia or diabetic meds and statins in advancing dementia particularly with weight loss.

Excellent question. I think we are discussing two different clinical scenarios. What we presented regarding aspirin was for primary prevention of major cardiovascular events in patients with diabetes( not including atrial fibrillation) and what you are referring to(patients with atrial fibrillation) is certainly a high-risk group for embolic stroke for which DOAC is a recommended primary prevention based on their CHADS-VASc score(CHA₂DS₂-VASc score). HAS-Bled can be used to determine the risk of bleeding as you know. I absolutely agree with you that embolic stroke due to atrial fibrillation are catastrophic and should be taken into account when discussing anticoagulation even in the setting of frequent falls.

Thank you for your thoughtful question. I have found using below communication technique of “FRAME” for negotiating deprescribing very helpful. This might require dedicated visits (with more than one visit) and often can be done via a video/telehealth
Communication Techniques for Deprescribing Conversations | Palliative Care Network of Wisconsin.

(Will defer to Dr See.) Answer coming soon!

Cynthia X. Pan Kathleen Adinolfi Robert S. Crupi

Cynthia X. Pan, MD, FACP, AGSF & Kathleen Adinolfi, MA, CCC-SLP, BCS-S & Robert S. Crupi, MD, FAEMSP

Thickened liquids may reduce and/or eliminate aspiration events primarily by slowing down the flow rate. This reduction in frequency of aspiration events can only be determined through instrumental swallow testing (VFSS, FEES) and cannot be determined based on a bedside clinical swallow assessment.

That said, an important distinction is that reduction of aspiration amount or frequency does not necessarily translate into reduced risk of aspiration pneumonia. Animal research has suggested that aspiration of thickened liquids may result in greater pulmonary inflammation and delayed pulmonary clearance when compared with plain water (Nativ-Zelter, et al 2018, 2021 and Araie et al 2020). However, increased pulmonary injury from thickened liquid aspiration has not been established in human studies, nor has it been proven that thickened liquids prevent aspiration pneumonia (Robbins et al 2008).

It is also important to note that increasing liquid viscosity may elevate risk for dehydration and increase oral and/or pharyngeal residue, potentially contributing to aspiration after the swallow (Li et al, 2025).

These considerations further support the idea presented in our lecture that swallowing evaluations should never be interpreted as binary: “pass/fail”, or “can/can’t eat”. Dysphagia management should be individualized. The question isn’t just, “Does aspiration occur?”. We must look at what is being aspirated, how frequently it occurs, and how effectively the person can clear the aspirated material. Swallowing physiology, pulmonary reserve, oral hygiene, hydration, patient preferences, and overall goals of care should all be considered in determining the dysphagia management plan.

I feel physicians should refer to dieticians as early as possible, for a variety of reasons.
We want to promote early identification of nutritional concerns and timely referral to a registered dietitian (RD/RDN) for patients with serious illness, with an emphasis on improving comfort, function, quality of life, and alignment with goals of care.

Potential Clinical Triggers for Dietitian Referral:

  • Unintentional Weight Loss
  • Inadequate Oral Intake
  • Swallowing or Feeding Difficulties
  • Nutrition-Related Symptoms
  • Frailty and Functional Decline
  • Advanced or Complex Illness
  • Complex Feeding Decisions
  • Patient and Family Concerns
  • Early dietitian involvement can support individualized nutrition care, informed decision-making, culturally responsive communication, and patient-centered goals of care.

    Of course – always communal a team.

Winona Tse

Winona Tse, MD

I think some groups says Lewy body dementia includes both the classic dementia with Lewy bodies, where there is a movement disorder and dementia occurring within a year of one another and Parkinson disease related dementia, where the dementia develops years after the PD diagnosis. Because to me the terminology may be confusing, one should be clear when discussing the dementia, which one you are referring to. I prefer to use Parkinson disease dementia, implying that it is the subcortical dementia that may follow after many years of the motor illness.

Nuplazid is only approved for Parkinson’s disease related psychosis or hallucinations at this time, so would be considered off label if used in Lewy body disease.

If patients have asthma or DM I try to avoid using propranolol which can exacerbate those conditions. Because there are limited options for medication use in ET, sometimes I will ask the internist if propranolol is possible to try in a patient with very mild asthma, if the internist thinks it might be tolerable, for example in a patient who has tried primidone already but not done well with that. I guess one has to do a risk/benefit analysis in terms of safety and tolerability of whatever agent you choose to use. Both primidone and propranolol can exacerbate depression, although that is not a common side effect in my experience.

Mary Ann McLaughlin

Mary Ann McLaughlin, MD, MPH, FACC

Answer coming soon!

Answer coming soon!

Andrew Dunn

Andrew Dunn, MD, MPH

Answer coming soon!

Answer coming soon!

Answer coming soon!

Answer coming soon!

Lauren A. Kelly

Lauren A. Kelly, MD, MPH, MS

Answer coming soon!

Answer coming soon!